Specifically, our data argue that a lack of IL-17 axis activation leads to decreased downstream production of inflammatory mediators known to drive NAFLD; including, CXCL10, CCL2, CCL22, and TNF. Here, CCL2 is linked to metabolic dysfunction-associated steatotic liver disease.